BlackRock Inc. raised its stake in MEDNAX Inc (NYSE:MD) by 3.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,125,250 shares of the company’s stock after buying an additional 245,301 shares during the quarter. BlackRock Inc. owned 8.69% of MEDNAX worth $351,662,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Fort Washington Investment Advisors Inc. OH increased its stake in shares of MEDNAX by 55.7% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 363,201 shares of the company’s stock worth $15,719,000 after purchasing an additional 130,001 shares during the last quarter. Bank of Montreal Can increased its stake in shares of MEDNAX by 6.8% during the 2nd quarter. Bank of Montreal Can now owns 210,277 shares of the company’s stock worth $9,102,000 after purchasing an additional 13,360 shares during the last quarter. Legal & General Group Plc increased its stake in shares of MEDNAX by 16.4% during the 1st quarter. Legal & General Group Plc now owns 137,616 shares of the company’s stock worth $7,655,000 after purchasing an additional 19,421 shares during the last quarter. Pzena Investment Management LLC increased its stake in shares of MEDNAX by 1.8% during the 2nd quarter. Pzena Investment Management LLC now owns 2,299,800 shares of the company’s stock worth $99,535,000 after purchasing an additional 41,088 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its stake in shares of MEDNAX by 40.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 10,030 shares of the company’s stock worth $434,000 after purchasing an additional 2,870 shares during the last quarter. Institutional investors own 95.51% of the company’s stock.
MD has been the subject of several recent analyst reports. Leerink Swann initiated coverage on shares of MEDNAX in a report on Thursday, July 12th. They set a “market perform” rating and a $50.00 price objective for the company. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Tuesday, August 7th. ValuEngine raised shares of MEDNAX from a “strong sell” rating to a “sell” rating in a report on Friday, August 3rd. Credit Suisse Group raised shares of MEDNAX from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $47.00 to $55.00 in a report on Friday, August 3rd. Finally, Stifel Nicolaus set a $47.00 price target on shares of MEDNAX and gave the company a “hold” rating in a report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $54.71.
Shares of MD stock opened at $48.23 on Friday. MEDNAX Inc has a 52-week low of $40.56 and a 52-week high of $63.04. The firm has a market capitalization of $4.44 billion, a PE ratio of 15.31, a price-to-earnings-growth ratio of 1.28 and a beta of 0.24. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.59.
MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, August 2nd. The company reported $1.07 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.07. MEDNAX had a net margin of 9.59% and a return on equity of 10.42%. The company had revenue of $915.90 million during the quarter, compared to analysts’ expectations of $911.77 million. During the same quarter in the prior year, the company posted $0.85 EPS. The business’s revenue was up 8.6% on a year-over-year basis. equities research analysts forecast that MEDNAX Inc will post 3.7 earnings per share for the current year.
In related news, insider John C. Pepia sold 3,500 shares of the stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $48.18, for a total transaction of $168,630.00. Following the completion of the sale, the insider now owns 30,148 shares in the company, valued at approximately $1,452,530.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Further Reading: Technical Analysis of Stocks, How Can It Help
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.